Pulmonary infection with microsporidia after allogeneic bone marrow transplantation.

abstract：:We report on 24 patients with leukemia (19 pts), congenital disorders (4 pts) or severe aplastic anemia (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions. All the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 ca...

journal_title：Bone marrow transplantation

authors： Lanino E,Lamparelli T,Dini G,Alessandrino EP,Aversa F,Calori E,Medugno D,Garbarino L,Locatelli F,Marenco P

更新日期：1993-01-01 00:00:00

abstract：:Optimal overnight (ON) storage of PBPC aphereses is becoming an increasingly important issue and different options for storing PBPC products exist. The survival of primitive progenitor cells is of major interest, as recent data suggest that these progenitors are not only important for long-term engraftment but also co...

journal_title：Bone marrow transplantation

authors： Petzer AL,Gunsilius E,Zech N,Clausen J,Hoflehner E,Nussbaumer W,Gastl G

更新日期：2000-01-01 00:00:00

abstract：:Sickle cell anemia (SCA) remains associated with high risks of morbidity and early death. Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for SCA. We report our experience with transplantation in a group of patients with the non-Black African variant and the Black African variant of SCA. This study ...

journal_title：Bone marrow transplantation

authors： Lucarelli G,Isgrò A,Sodani P,Marziali M,Gaziev J,Paciaroni K,Gallucci C,Cardarelli L,Ribersani M,Alfieri C,De Angelis G,Armiento D,Andreani M,Testi M,Amato A,Akinyanju OO,Wakama TT

更新日期：2014-11-01 00:00:00

abstract：:Limited information is available regarding the incidence and features of lymphocyte expansions after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Large granular lymphocytes (LGL) expansions have been reported after bone marrow or peripheral blood, but not after unrelated cord blood (UCB) allo-HSCT, ...

journal_title：Bone marrow transplantation

authors： Le Bris Y,Guillaume T,Ménard A,Illiaquer M,Martin J,Malard S,Duquesne A,Peterlin P,Debord C,Robillard N,Eveillard M,Wuillème S,Delaunay J,Mohty M,Garnier A,Moreau P,Béné MC,Chevallier P

更新日期：2017-06-01 00:00:00

abstract：:One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma. While this observation has largely been made in patients under the age of 65 years, there is evidence to suggest that the conclusions can be extrapolate...

journal_title：Bone marrow transplantation

authors： Mehta J,Singhal S

更新日期：2007-12-01 00:00:00

abstract：:Bone marrow transplantation is known to be associated with considerable morbidity and mortality. The aim of this study was to determine the influence of nutritional status and development of sick euthyroid syndrome as prognostic factors for outcome after BMT. In 100 patients who underwent transplantation the following...

journal_title：Bone marrow transplantation

authors： Schulte C,Reinhardt W,Beelen D,Mann K,Schaefer U

更新日期：1998-12-01 00:00:00

abstract：:A 16-month-old girl diagnosed with osteopetrosis underwent an unrelated, partially matched (with major mismatch at A locus) cord blood stem cell transplant. Twelve months later she developed severe acute autoimmune hemolytic anemia (AIHA). Immunophenotype analysis of lymphocyte subsets 8 months post transplant showed ...

journal_title：Bone marrow transplantation

authors： Sevilla J,González-Vicent M,Madero L,Díaz MA

更新日期：2001-07-01 00:00:00

abstract：:The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

journal_title：Bone marrow transplantation

authors： Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

更新日期：1993-01-01 00:00:00

abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

journal_title：Bone marrow transplantation

authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

更新日期：1998-05-01 00:00:00

abstract：:In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2...

journal_title：Bone marrow transplantation

authors： Kerep AZ,Broome J,Pirsl F,Curtis LM,Steinberg SM,Mitchell SA,Cowen EW,Pichard DC,Joe GO,Comis LE,Mays JW,Datiles MB 3rd,Stratton P,Zolton J,Berger A,Hendricks J,Kenyon M,Baruffaldi J,Titarenko I,Pulanic D,Baird K

更新日期：2019-01-01 00:00:00

abstract：:From 1987 to 1991, 26 patients with CML and a median age of 31 years received allogeneic BMT from a partially mismatched related donor (PMRD) who shared at least one haplotype with the recipient. Nine patients were in accelerated phase (AP), and 11 patients were in blast crisis (BC) at the time of BMT. Patients were m...

journal_title：Bone marrow transplantation

authors： Bishop MR,Henslee-Downey PJ,Anderson JR,Romond EH,Marciniak E,Yankey R,Reeves M,Thompson JS

更新日期：1996-10-01 00:00:00

abstract：:Introduction of genes conferring drug resistance into hematopoietic cells may allow for improved chemotherapy by protection of normally drug-sensitive cells from the toxic side-effects of antitumor agents. We recently reported that transplantation of murine marrow transgenic for drug-resistant dihydrofolate reductase ...

journal_title：Bone marrow transplantation

authors： James R,May C,Diers M,Wagner J,McIvor R

更新日期：1999-10-01 00:00:00

abstract：:Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to...

journal_title：Bone marrow transplantation

authors： Oblon DJ,Paul S,Yankee R

更新日期：1997-09-01 00:00:00

abstract：:Cord blood banks are being developed in the United States and Europe. In The Netherlands, the EuroCord Nederland Foundation (ECN) has been established to coordinate the development of a national cord blood bank for unrelated transplants. The aim of ECN is to collect at least 5000 transplants for patients who lack an H...

journal_title：Bone marrow transplantation

authors： Jacobs HC,Falkenburg JH

更新日期：1998-07-01 00:00:00

abstract：:With the purpose of contributing to a better knowledge of the phenotypic characteristics and functional activity of umbilical cord blood (UCB) lymphocytes, we have carried out extensive immunophenotyping of these cells, evaluated their immune response to polyclonal and allogeneic activation and then compared these res...

journal_title：Bone marrow transplantation

authors： Paiva A,Freitas A,Loureiro A,Couceiro A,Martinho A,Simões O,Santos P,Tomaz J,Pais ML,Brêda Coimbra H

更新日期：1998-07-01 00:00:00

abstract：:Cyclosporine A (CsA) therapy based on 2-h concentrations (C2) after oral administration has demonstrated low acute rejection rates after solid organ transplantation. We analysed the correlation between C2 and trough (C0) levels of oral CsA therapy in samples obtained twice in consecutive weeks from 58 patients during ...

journal_title：Bone marrow transplantation

authors： Barkholt L,Remberger M,Bodegård H,Ringdén O,Böttiger Y

更新日期：2007-10-01 00:00:00

abstract：:We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematoc...

journal_title：Bone marrow transplantation

authors： Martínez AM,Sastre A,Muñoz A,Badell I,Maldonado MS,Cubells J

更新日期：1998-07-01 00:00:00

abstract：:The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m(2) plus doxorubicin 80 mg/m(2)...

journal_title：Bone marrow transplantation

authors： García-Rayo S,Pérez-Calvo J,Martín-Algarra S,Martínez-Monge R,Fernández-Hidalgo O,Subirá L,Martínez-Aguillo M,Rebollo J,Azinovic I,Brugarolas A

更新日期：2001-08-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who...

journal_title：Bone marrow transplantation

authors： Imahashi N,Suzuki R,Fukuda T,Kakihana K,Kanamori H,Eto T,Mori T,Kobayashi N,Iwato K,Sakura T,Ikegame K,Kurokawa M,Kondo T,Iida H,Sakamaki H,Tanaka J,Kawa K,Morishima Y,Atsuta Y,Miyamura K

更新日期：2013-01-01 00:00:00

abstract：:Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We analyzed HCT outcomes by time of transplant disease variables, including (1) blast percentage, (2) percentage of ...

journal_title：Bone marrow transplantation

authors： Trottier BJ,Sachs Z,DeFor TE,Shune L,Dolan M,Weisdorf DJ,Ustun C,Warlick ED

更新日期：2016-02-01 00:00:00

abstract：:This report summarizes the Spanish experience of 62 cases of allogeneic transplantation of purified CD34+ cells from peripheral blood. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were purified using one of two methods: Ceprate (n = 38), or Isolex 300 (n = 24). Si...

journal_title：Bone marrow transplantation

authors： Urbano-Ispizua A,Solano C,Brunet S,de la Rubia J,Odriozola J,Zuazu J,Figuera A,Caballero D,Martínez C,García J,Sanz G,Torrabadella M,Alegre A,Pérez-Oteiza J,Jurado M,Oyonarte S,Sierra J,García-Conde J,Rozman C

更新日期：1998-06-01 00:00:00

abstract：:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

journal_title：Bone marrow transplantation

authors： Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

更新日期：2011-02-01 00:00:00

abstract：:Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

journal_title：Bone marrow transplantation

authors： D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

更新日期：2001-09-01 00:00:00

abstract：:Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI +/- fludarabine and post...

journal_title：Bone marrow transplantation

authors： Frère P,Baron F,Bonnet C,Hafraoui K,Pereira M,Willems E,Fillet G,Beguin Y

更新日期：2006-02-01 00:00:00

abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

journal_title：Bone marrow transplantation

authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

更新日期：2015-06-01 00:00:00

abstract：:High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma. This treatment is associated with non-selective cytotoxicity, causing oral mucositis as the major non-hematological side-effect. Amifostine is a cytoprotector which prevents toxicity induced by anticancer therapy. We p...

journal_title：Bone marrow transplantation

authors： Thieblemont C,Dumontet C,Saad H,Roch N,Bouafia F,Arnaud P,Hequet O,Espinouse D,Salles G,Roy P,Eljaafari-Corbin A,Du Manoir-Baumgarten C,Coiffier B

更新日期：2002-12-01 00:00:00

abstract：:Allogeneic SCT remains the only potential cure for patients with thalassemia. However, most BMT candidates lack a suitable family donor and require an unrelated donor (UD). We evaluated whether BMT using UDs in high-risk adult thalassemia patients can offer a probability of cure comparable to that reported employing a...

journal_title：Bone marrow transplantation

authors： La Nasa G,Caocci G,Argiolu F,Giardini C,Locatelli F,Vacca A,Orofino MG,Piras E,Addari MC,Ledda A,Contu L

更新日期：2005-12-01 00:00:00

abstract：:Estimation of CD34 expression is widely used to detect and quantify progenitor cells in haemopoietic tissues used as stem cell sources for transplantation. Mouse monoclonal antibodies to CD34 recognise different epitopes of the mucin-like sialoglycoprotein. These epitopes can be grouped into three classes by their dif...

journal_title：Bone marrow transplantation

authors： Titley I,Healy LE,Scott M,Amos TA,Gordon MY

更新日期：1995-10-01 00:00:00

abstract：:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

journal_title：Bone marrow transplantation

authors： Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

更新日期：1994-06-01 00:00:00

abstract：:Following engraftment of donor hematopoietic cells and induction of host-versus-graft tolerance, immunocompetent lymphocytes of donor origin can induce graft-versus-leukemia (GVL) and graft-versus-tumor (GVT) effects. Engraftment of allogeneic bone marrow cells can be accomplished following non-myeloablative condition...

journal_title：Bone marrow transplantation

authors： Slavin S,Or R,Prighozina T,Gurevitch O,Aker M,Panighari S,Shapira M,Nagler A

更新日期：2000-05-01 00:00:00